Biodrugs

Papers
(The H4-Index of Biodrugs is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry262
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond173
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making94
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor90
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome79
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis66
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis63
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy56
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design51
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery45
Acknowledgement to Referees44
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials42
CAR-T Cells and the Kidney: Insights from the WHO Safety Database36
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?36
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart34
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies33
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202232
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy31
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic31
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review30
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?30
Malaria Vaccines: Progress to Date29
Progress and Challenges in the Treatment of Fabry Disease29
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data27
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase27
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer26
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?26
0.38012504577637